Seviteronel

Drug Profile

Seviteronel

Alternative Names: VT-464

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Viamet Pharmaceuticals
  • Developer Innocrin Pharmaceuticals; Viamet Pharmaceuticals
  • Class Antiandrogens; Antineoplastics; Fluorine compounds; Naphthalenes; Propanols; Small molecules; Triazoles
  • Mechanism of Action Androgen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Prostate cancer

Most Recent Events

  • 20 Jun 2017 The EMEA grants Small and Medium Enterprise (SME) status to Innocrin
  • 17 May 2017 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 06 Apr 2017 Seviteronel receives Fast Track designation for Breast cancer [PO] (Late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top